A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 810 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Daratumumab October 14, 2024 Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis April 10, 2025 Ενθαρρυντικά δεδομένα για ασθενείς με προχωρημένο μελάνωμα που έλαβαν θεραπεία με... June 24, 2019 First-Line 177Lu-Dotatate Plus Octreotide LAR Significantly Extends PFS in Patients with... June 13, 2024 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria COVID-19 Takes the Life of a Widowed Mother of 6 Who... To Improve Immunotherapy, Researchers Look at Limiting Cancer’s Access to Sugar... FDA Grants Accelerated Approval to Umbralisib for Marginal Zone and Follicular...
